- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05930353
Psychometric Validation of a French-language Version of the PERMA-Profiler: Tools for Assessing Multidimensional Subjective Well-being (PERMAPROFILER2)
February 11, 2025 updated by: Centre Hospitalier Universitaire de Nīmes
The main objective of this study is to carry out the psychometric validation of the PERMA-Profiler in a population representative of the general French population and in comparison with the reference questionnaire The PERMA-Profiler.
Study Overview
Study Type
Observational
Enrollment (Estimated)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nimes, France, 30029
- CHU de Nîmes
-
Contact:
- Julie Jourdan
- Phone Number: 04.66.68.34.26
- Email: julie.jourdan@chu-nimes.fr
-
Contact:
- aurelie SCHANDRIN
- Phone Number: 0466683426
- Email: aurelie.schandrin@chu-nimes.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
general population
Description
Inclusion Criteria:
- Adult (≥18 years).
- Person able to read and understand French
- Person willing to participate in this study
Exclusion Criteria:
- The person does not understand the French language
- Person has a history of traumatic brain injury
- The person refuses to participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PERMA PROFILER French Version: diagnostic properties
Time Frame: DAY 0
|
sensitivity, specificity
|
DAY 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2025
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
June 26, 2023
First Submitted That Met QC Criteria
June 26, 2023
First Posted (Actual)
July 5, 2023
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 11, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2023/JJ-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychiatric Disorder
-
Stéphane MorandiUniversity of LausanneNot yet recruitingPsychiatric Disorder | Involuntary Psychiatric HospitalizationSwitzerland
-
Mental Health Services in the Capital Region, DenmarkUniversity of CopenhagenRecruitingMental Illness | Behavior Disorders | Psychiatric Disorder | Mental Disorder | Severe Mental Disorder | Psychiatric Illness | Diagnosis, Psychiatric | Psychiatric Disease | Diagnosis DualDenmark
-
Medical University InnsbruckActive, not recruiting
-
Michael RuferUniversity of ZurichEnrolling by invitationHealth Care Utilization | Chronic Psychiatric Disorder | Psychiatric Hospitalization | Intensive Care Psychiatric Disorder | Rehospitalization | High Utilization / Heavy UseSwitzerland
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Massachusetts General HospitalTerminatedObsessive-Compulsive Disorder | Pediatric Psychiatric DisorderUnited States
-
University of Lausanne HospitalsCompletedPsychiatric Disorder | Involuntary Psychiatric HospitalizationSwitzerland
-
Brigham and Women's HospitalActive, not recruitingDepression | Mood Disorders | Depressive Disorder, Major | Psychiatric Disorder | Mental DisorderUnited States
-
The Miriam HospitalCompletedTobacco Smoking | Psychiatric Disorder | Psychiatric HospitalizationUnited States
-
University of SalzburgEnrolling by invitationMental Illness | Psychiatric Disorder | Mental DisorderAustria
Clinical Trials on COHORT
-
Y Biologics Inc.Novotech (Australia) Pty LimitedActive, not recruitingAdvanced Solid TumorsKorea, Republic of, Thailand, Australia
-
Institut du Cancer de Montpellier - Val d'AurelleRecruiting
-
Uniquity One (UNI)CompletedHealthyUnited States
-
XOMA (US) LLCCompletedCongenital HyperinsulinismUnited Kingdom, United States
-
MedImmune LLCCompletedHealthyUnited States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
-
AstraZenecaCompletedCOVID-19, SARS-CoV-2Japan
-
University of FloridaRecruitingPlantar FasciitisUnited States
-
Immunwork, Inc.CompletedOverweight and ObesityAustralia
-
Kangabio AUSTRALIA LTD PTYActive, not recruiting